Basophil histamine release activity and disease severity in chronic idiopathic urticaria

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 3, 2008, Pages 244-249

  Baker, Rosalyn ^a   Vasagar, Kavitha ^a   Ohameje, Nkiruka ^a   Gober, Laura ^a   Chen, Suephy C ^b,c   Sterba, Patricia M ^a   Saini, Sarbjit S ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FORMYLMETHIONYLLEUCYLPHENYLALANINE; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; POLYCLONAL ANTIBODY;

ABSENTEEISM; ADULT; ARTICLE; BASOPHIL; BASOPHIL DEGRANULATION; CELL ISOLATION; CHRONIC IDIOPATHIC URTICARIA; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FLUOROMETRY; HEALTH CARE UTILIZATION; HISTAMINE RELEASE; HUMAN; IDIOPATHIC DISEASE; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; REGRESSION ANALYSIS; URTICARIA;

EID: 40849136234     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60449-8     Document Type: Article

References (28)

1. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105:664-672.
2. Zuberbier T. Urticaria. Allergy. 2003;58:1224-1234.
3. Kaplan AP, Horakova Z, Katz SI. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol. 1978;61:350-354.
4. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol. 2003;3:363-368.
5. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004;114:465-474, quiz 475.
6. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol. 2001;107:1056-1062.
7. Sabroe RA, Fiebiger E, Francis DM, et al. Classification of anti-FcεRIα and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol. 2002;110:492-499.
8. Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol. 2005;5:403-407.
9. Sabroe RA, Francis DM, Barr RM, Black AK, Greaves MW. Anti-FcεRI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol. 1998;102:651-658.
10. Kern F, Lichtenstein LM. Defective histamine release in chronic urticaria. J Clin Invest. 1976;57:1369-1377.
11. Vonakis BM, Vasagar K, Gibbons SP Jr, et al. Basophil FcεRIα histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007;119:441-448.
12. Gober LM, Sterba PM, Baker R, Vasagar K, Vonakis BM, Saini SS. Longitudinal examination of basophil functional phenotypes and disease activity in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007;119:S312.
13. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol. 2006;30:47-51.
14. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197-201.
15. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154:294-298.
16. Marsland AM, Soundararajan S, Joseph K, Kaplan AP. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clin Exp Allergy. 2005;35:554-559.
17. Saini SS, Richardson JJ, Wofsy C, Lavens-Phillips S, Bochner BS, Macglashan DW Jr. Expression and modulation of FcεRIα and FcεRIβ in human blood basophils. J Allergy Clin Immunol. 2001;107:832-841.
18. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16. J Cutan Med Surg. 2001;5:105-110.
19. Greaves MW. Antihistamine treatment. BMJ (Clin Res Ed). 1981;283:1435-1436.
20. O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol. 1998;138:101-106.
21. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria. J Am Acad Dermatol. 2003;48:535-541.
22. Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, Martinelli N, Rini GB. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114:619-625.
23. Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria. J Am Acad Dermatol. 1999;40:443-450.
24. Grattan CE, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls. Clin Exp Allergy. 2003;33:337-341.
25. Yasnowsky KM, Dreskin SC, Efaw B, et al. Chronic urticaria sera increase basophil CD203c expression. J Allergy Clin Immunol. 2006;117:1430-1434.
26. Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect costs of chronic idiopathic urticaria. Arch Dermatol. In press.
27. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life. Allergy. 2005;60:1073-1078.
28. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152:289-295.